Literature DB >> 2379534

Uricosuric effect of different doses of irtemazole in normouricaemic subjects.

U Gresser1, I Kamilli, U Kronawitter, N Zöllner.   

Abstract

Irtemazole 12.5 to 50 mg in 6 healthy, normouricaemic subjects caused a maximal decrease in plasma uric acid (after 8 to 12 h) of 46.5%. The uricosuric effect began during the first 60 min after drug administration and it lasted for 7 to 24 h. Renal uric acid excretion returned to its base line value after 8 to 16 h and uric acid clearance after 10.0 to 12.0 h. Doses of irtemazole between 12.5 and 37.5 mg produced a dose-related rise in the uricosuric effect. There was no essential difference between the uricosuric effect of 37.5 mg and 50 mg irtemazole. The D50 dose (that producing a half-maximal effect) was between 16.3 mg and 34.2 mg, (average 24.7 mg). The value of irtemazole in the management of hyperuricaemia and gout remains to be determined.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2379534     DOI: 10.1007/bf02336689

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  9 in total

1.  Enzymatic determination of uric acid; with detailed directions.

Authors:  E PRAETORIUS; H POULSEN
Journal:  Scand J Clin Lab Invest       Date:  1953       Impact factor: 1.713

2.  [Differential indications for uricosuric drugs and allopurinol].

Authors:  W Gröbner; N Zöllner
Journal:  Klin Wochenschr       Date:  1989-03-01

3.  Effect of single oral doses of benzbromarone on serum and urinary uric acid.

Authors:  A K Jain; J R Ryan; F G McMahon; R J Noveck
Journal:  Arthritis Rheum       Date:  1974 Mar-Apr

4.  [Effect of benzbromaronum on the renal uric acid excretion in healthy persons].

Authors:  N Zöllner; W Dofel; W Gröbner
Journal:  Klin Wochenschr       Date:  1970-04-01

5.  [Uricosuric agents].

Authors:  N Zöllner; W Gröbner
Journal:  Arzneimittelforschung       Date:  1971-10

6.  Uricosuric effect of irtemazole in healthy subjects.

Authors:  U Gresser; N Zöllner
Journal:  Klin Wochenschr       Date:  1989-10-02

Review 7.  Benzbromarone: a review of its pharmacological properties and therapeutic use in gout and hyperuricaemia.

Authors:  R C Heel; R N Brogden; T M Speight; G S Avery
Journal:  Drugs       Date:  1977-11       Impact factor: 9.546

8.  A new uricosuric substance 5-[(1H-imidazol-1-yl)phenylmethyl]-2-methyl-1H-benzimidazole (C18H16N4).

Authors:  U Gresser; N Zöllner
Journal:  Klin Wochenschr       Date:  1989-06-15

Review 9.  Clinical pharmacokinetics of probenecid.

Authors:  R F Cunningham; Z H Israili; P G Dayton
Journal:  Clin Pharmacokinet       Date:  1981 Mar-Apr       Impact factor: 6.447

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.